Le Lézard
Classified in: Business
Subject: LAW

Notice from the Office of the Secretary - Ontario Securities Commission


AURORA CANNABIS INC., File No. 2017-71

THE SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS OF CANNIMED THERAPEUTICS INC., File No. 2017-73

CANNIMED THERAPEUTICS INC., File No. 2017-74

TORONTO, Dec. 20, 2017 /CNW/ - Take notice that the hearing in the above named matter scheduled to be heard on December 20, 2017 at 9:00 a.m. will be heard on December 20, 2017 at 1:00 p.m.

OFFICE OF THE SECRETARY
GRACE KNAKOWSKI
SECRETARY TO THE COMMISSION

SOURCE Ontario Securities Commission


These press releases may also interest you

at 08:05
Cutera, Inc. ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024....

at 08:05
The Beauty Health Company , home to flagship brand Hydrafacialtm, today announced it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. The Company will host an investor conference call at 4:30 p.m. Eastern...

at 08:05
Bragg Gaming Group Inc. ( NASDAQ: BRAG , TSX: BRAG ) (" Bragg " or the " Company"), a global B2B gaming technology and content provider, announced today that it will release its first quarter 2024 financial results prior to the opening of the...

at 08:05
Piper Sandler Companies has released its most recent financial results. The complete earnings release can be found on the firm's website at pipersandler.com/earnings Join the earnings conference call on Friday, April 26, 2024 at 8:00 a.m. CT....

at 08:05
CPI Card Group Inc. ("CPI Card Group"), a payments technology company and leading provider of credit, debit, and prepaid card and digital solutions, including Software-as-a-Service-based instant issuance, today announced it will host a webcast and...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...



News published on and distributed by: